Aveo Pharmaceuticals Inc Revenue Growth Rates (AVEO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aveo Pharmaceuticals Inc   (AVEO)
 

AVEO's Revenue Growth by Quarter and Year

Aveo Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AVEO Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 30.45
2nd Quarter June 25.30
1st Quarter March 20.92
FY 76.67

AVEOs Annual Revenue
Aveo Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 42.49 millions
Aveo Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 6.02 millions
Aveo Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 28.80 millions
Aveo Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 5.41 millions
Aveo Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 7.58 millions




AVEO Revenue third quarter 2022 Y/Y Growth Comment
Aveo Pharmaceuticals Inc reported Revenue surge of 100.72% year on year in the third quarter 2022, to $ 30.45 millions, this is lower than Aveo Pharmaceuticals Inc 's recent average Revenue surge of 428.46%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue growth. While Aveo Pharmaceuticals Inc ' s Revenue doubling of 100.72% ranks overall at the positon no. 397 in the third quarter 2022.


AVEO Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 1905.62 % 17.11 % -48.65 %
3rd Quarter September 100.72 % 321.39 % -86 % 941.3 %
2nd Quarter June 234.66 % 908 % 7.14 % 62.79 %
1st Quarter March 989.58 % 146.15 % -51.55 % 56.31 %
FY   - 605.98 % -79.09 % -

Financial Statements
Aveo Pharmaceuticals Inc 's third quarter 2022 Revenue $ 30.45 millions AVEO's Income Statement
Aveo Pharmaceuticals Inc 's third quarter 2021 Revenue $ 15.17 millions Quarterly AVEO's Income Statement


AVEO Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 17.67 % -75.28 % -97.05 %
3rd Quarter September 20.35 % 100.66 % 380 % 3574.29 %
2nd Quarter June 20.94 % 293.75 % -3.85 % -56.52 %
1st Quarter March 17.2 % 115.73 % 2.63 % 8.78 %
FY (Year on Year)   - 605.98 % -79.09 % -


Back to AVEO Growth rate Comparisons >> Back to AVEO Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #99
Overall #397

Revenue Y/Y Growth Statistics
High Average Low
4633.44 % 428.46 % -99.36 %
(Mar 31 2014)   (Mar 31 2015)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #99
Overall #397
Revenue Y/Y Growth Statistics
High Average Low
4633.44 % 428.46 % -99.36 %
(Mar 31 2014)   (Mar 31 2015)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Aveo Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11211.94 % 623.62 % -97.92 %
(Sep 30 2015)  


AVEO's III. Quarter Q/Q Revenue Comment
Aveo Pharmaceuticals Inc achieved in the III. Quarter 2022 below company average Revenue jump of 20.35% quarter on quarter, to $ 30.45 millions.

Within Major Pharmaceutical Preparations industry 26 other companies have achieved higher Revenue quarter on quarter growth. While Aveo Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 171.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #27
Healthcare Sector #38
Overall #171
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #27
Healthcare Sector #38
Overall #171
Revenue Q/Q Growth Statistics
High Average Low
11211.94 % 623.62 % -97.92 %
(Sep 30 2015)  


AVEO's III. Quarter Q/Q Revenue Comment
Aveo Pharmaceuticals Inc achieved in the III. Quarter 2022 below company average Revenue jump of 20.35% quarter on quarter, to $ 30.45 millions.

Within Major Pharmaceutical Preparations industry 26 other companies have achieved higher Revenue quarter on quarter growth. While Aveo Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 171.


Aveo Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 94.52 $ 79.24 $ 61.49 $ 42.49 $ 25.54
Y / Y Revenue Growth (TTM) 270.15 % 467.55 % 759.45 % 606 % 333.02 %
Year on Year Revenue Growth Overall Ranking # 83 # 22 # 16 # 35 # 81
Seqeuential Revenue Change (TTM) 19.28 % 28.86 % 44.71 % 66.41 % 82.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 438 # 95 # 105 # 100 # 51


Cumulative Revenue growth Comment
Assuming the Aveo Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2022, Aveo Pharmaceuticals Inc would have reprted above average annual Revenue surge of 270.15% year on year, of $ 95 millions.
This marks a slow-down of the companys growth trends and from the 467.55% surge in Jun 30 2022.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 83.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 21
Overall # 83

Revenue TTM Y/Y Growth Statistics
High Average Low
1504.46 %
 199.94 %
-93.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 87
S&P 500 # 438
Cumulative Revenue growth Comment
Assuming the Aveo Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2022, Aveo Pharmaceuticals Inc would have reprted above average annual Revenue surge of 270.15% year on year, of $ 95 millions.
This marks a slow-down of the companys growth trends and from the 467.55% surge in Jun 30 2022.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 83.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 21
Overall # 83

Revenue TTM Y/Y Growth Statistics
High Average Low
1504.46 %
199.94 %
-93.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 87
S&P 500 # 438




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AVEO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Geron Corporation172.48%$ 172.477 millions
Xeris Biopharma Holdings Inc 168.76%$ 168.761 millions
Albireo Pharma inc 168.34%$ 168.341 millions
Comera Life Sciences Holdings Inc 167.56%$ 167.565 millions
Aligos Therapeutics Inc 167.14%$ 167.144 millions
Macrogenics Inc 166.47%$ 166.467 millions
Celldex Therapeutics inc 166.01%$ 166.013 millions
Sunshine Biopharma Inc 163.63%$ 163.633 millions
Lucira Health Inc 157.53%$ 157.526 millions
Prophase Labs Inc 155.49%$ 155.490 millions
Notable Labs Ltd 141.71%$ 141.709 millions
Procept Biorobotics Corporation134.76%$ 134.760 millions
Lantheus Holdings Inc 134.43%$ 134.432 millions
Agile Therapeutics Inc133.26%$ 133.256 millions
Blueprint Medicines Corporation132.74%$ 132.745 millions
Sanara Medtech Inc 123.98%$ 123.982 millions
Sangui Biotech International Inc121.06%$ 121.061 millions
Gelesis Holdings Inc 120.70%$ 120.703 millions
Sigilon Therapeutics Inc 118.39%$ 118.387 millions
Rxsight Inc 118.03%$ 118.026 millions
Precision Optics Corporation Inc 117.66%$ 117.661 millions
Orasure Technologies Inc116.00%$ 116.004 millions
Bionik Laboratories Corp 113.34%$ 113.337 millions
Somalogic Inc 108.65%$ 108.648 millions
Aravive Inc 105.47%$ 105.473 millions
Marizyme Inc 104.25%$ 104.251 millions
Effector Therapeutics Inc 103.04%$ 103.044 millions
Shockwave Medical Inc 101.57%$ 101.565 millions
Renalytix Plc101.04%$ 101.037 millions
Aveo Pharmaceuticals Inc 100.68%$ 100.679 millions


About Aveo Pharmaceuticals Inc Revenue Growth Rates (AVEO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aveo Pharmaceuticals Inc (CIK 1325879).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-22-028635
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aveo Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.